Shaw Local Radio Podcast: Talk-Line with Steve Marco interviews Betty Clementz, Relay for Life preview
Jun. 13—Listen to "Talk-Line: Betty Clementz, Relay for Life preview" on Spreaker.
The TALK-LINE interview for June 12 featured the Chairperson of the 2025 Sauk Valley Relay For Life event, Betty Clementz, discussing this Saturday's activities at the Westwood Sports Complex in Sterling, from the recognition of those that have participated in past "Relay" events to the "Luminaria" spotlight of those that have lost the fight with cancer, at the 30th annual event benefitting the American Cancer Society.
Like what you hear? Be sure to visit WIXN, part of Shaw Local Radio.
We're also available on Apple Podcasts and Spotify.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
16 hours ago
- Newsweek
Gen Zer Reaches Final Stage of Chemo—Has No Idea Devastating News Is Coming
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. When Alexis Klimpl discovered a grape-sized lump in her breast, her gut immediately told her it was cancer. But due to her young age, she tried to convince herself it couldn't be. However, a series of tests and scans confirmed the worst: she had stage 2 triple-positive breast cancer at just 24 years old. Now, one year later, the publicist from San Diego, California, is in remission. But she's also navigating early menopause brought on by her treatment. "I can't have kids for 10 more years because of the medication I'm on," she told Newsweek. Klimpl takes Lupron, a drug used to reduce the risk of hormone-receptor-positive breast cancer returning in premenopausal women following surgery and other treatments. She also takes Letrozole, a hormone blocker. "I never thought I'd be in menopause at 25," she said. "I have 10 to 15 hot flashes a day, night sweats, ongoing hair loss, vaginal dryness and mood swings." Most women begin the menopausal transition between the ages of 45 and 55, with symptoms often lasting for several years. Breast cancer, too, is typically associated with older women—the American Cancer Society reports that the median age at diagnosis is 62. Although uncommon, a small percentage of cases do occur in women under 45. L-R: Klimpl with her partner and Klimpl sitting in the hospital during cancer treatment. L-R: Klimpl with her partner and Klimpl sitting in the hospital during cancer treatment. Alexis Klimpl Dr. Mary Jane Minkin, the co-director of the sexuality, intimacy and menopause for cancer survivors program at Smilow Cancer Hospital in New Haven, Connecticut, explained to Newsweek why patients like Klimpl go through a medicated menopause. "The problem here is that for a woman who has (presumed) estrogen receptor positive breast cancer, all oncologists would want to avoid giving her estrogen, and indeed would probably give her medications to minimize her own body's production of any estrogen from any non-ovarian source," Minkin said. With no family history of breast cancer, Klimpl and her mother were devastated by the diagnosis. "I thought I was too young to have cancer," she told Newsweek, explaining that she initially hoped it was just a cyst, but she could feel it growing. "When I was diagnosed, the doctors didn't know how it happened. They said it's rare at my age. My mom broke down. Seeing her face—I'll never forget that image," Klimpl said. A friend set up a GoFundMe page for Klimpl that raised $23,000. Half of the funds went toward egg freezing, during which 36 eggs were retrieved. The rest helped cover the costs of six surgeries, each priced at $3,000. L-R: Klimpl flashing a peace sign and with her mother during a hospitalization. L-R: Klimpl flashing a peace sign and with her mother during a hospitalization. Alexis Klimpl/Alexis Klimpl Klimpl underwent six rounds of chemotherapy over the course of nearly five months and was officially declared cancer-free in January of this year. Despite genetic tests showing no inherited cancer risk, she chose to have a double mastectomy. "In my eyes, my breasts betrayed me. They didn't have my back, so I wanted them gone," she said. Klimpl has since undergone breast reconstruction, which she lightheartedly refers to on Instagram (@lexiklimpl) as "the only positive" of her cancer experience. Reflecting on the past year, she told Newsweek: "As a young person, you feel invincible—but being diagnosed at such a young age really put my life into perspective." "It strengthened my relationships with friends and family because they showed up for me in ways I'll never forget. I've realized that we often don't know how to be there for others when we're just trying to keep ourselves together," she said. "I'm finally at a stage where it feels like everything is behind me. I'm returning to my life—but it's strange. I thought that hearing the words 'cancer-free' would bring instant relief, that it would be the moment the stress disappeared. But it wasn't. Recovery is more complex than I expected."
Forbes
a day ago
- Forbes
Safer Sunscreens: Selecting Healthy and Reef-Safe Products
Choosing sunscreen that is healthy and reef-safe can be challenging. As summer temperatures soar and we flock to beaches, pools, and outdoor recreation areas, choosing the right sunscreen is important but challenging. On one hand, the American Cancer Society estimates that more than 100,000 Americans will be diagnosed with invasive melanoma in 2025. On the other hand, some sunscreen ingredients are linked to hormone disruption and other health harms. And then there's the fact that approximately 14,000 tons of sunscreen wash into coral reefs annually, contributing to the destruction of marine ecosystems. How can our sunscreen choices balance these concerns? Mineral Sunscreens Are Safer Than Chemical Sunscreens Under current FDA guidelines, only two active ingredients are classified as "Generally Recognized As Safe and Effective" (GRASE): zinc oxide and titanium dioxide. These mineral-based compounds work by creating a physical barrier on the skin that reflects and scatters ultraviolet radiation away from the body. In contrast, the FDA has requested additional safety data for 12 chemical sunscreen ingredients, including avobenzone, oxybenzone, octinoxate, and octocrylene. This is because there is growing evidence that these chemicals can be absorbed through the skin and may pose health risks. Mineral sunscreens are also more reef-safe. Oxybenzone and octinoxate, two of the most common chemical sunscreen ingredients, have been identified as primary drivers of coral bleaching, a process that strips corals of their life-sustaining algae and leaves them vulnerable to disease and death. These chemicals also disrupt the endocrine systems and brains of fish. Mineral-based alternatives like zinc oxide and titanium dioxide pose no known harm to coral reefs or other marine life. Sunscreen Lotions Are Safer Than Sprays And Mists While spray sunscreens are convenient, they may be the worst choice for both human health and the environment. This is because aerosol delivery systems release significant quantities of sunscreen into the air rather than onto skin. These airborne particles can travel considerable distances before settling on surfaces, potentially contaminating areas far from where we applied the sunscreen. When used near beaches, lakes, or other water bodies, spray sunscreens directly introduce chemicals into aquatic environments without the intermediate step of skin contact. There is also a risk of inadvertent inhalation of spray sunscreen particles, especially when products are used on children. Additionally, achieving adequate coverage with spray formulations proves challenging, often resulting in uneven protection and increased sunburn risk. Picking The Best Sunscreens How can you tell which sunscreens are safe for your health and for reefs? Check the label. The Surfrider Foundation's "HEL list" (Harmful Elements List) provides a clear framework for ingredients to avoid: oxybenzone, octinoxate, octocrylene, 4-methylbenzylidene camphor, PABA, parabens, triclosan, microplastics like 'exfoliating beads,' and nanoparticles. The organization emphasizes avoiding nano-sized zinc oxide and titanium dioxide particles, which may pose risks to marine ecosystems despite their mineral origin. If you're looking for specific brand recommendations, here are some expert guides: There are also helpful shopping resources like Clearya. This free platform functions as both a browser extension and mobile app, automatically scanning product ingredients against comprehensive databases of potentially harmful chemicals. You can scan sunscreens while shopping on major retail platforms like Amazon, Sephora, and Walmart, receiving instant feedback on product safety. Beyond Sunscreen: Comprehensive Sun Safety Strategies Although sunscreen is effective, it's important to remember that physical barriers are our first line of defense against UV radiation. Wide-brimmed hats provide excellent protection for faces, necks, and ears—areas often inadequately covered by sunscreen application. Lightweight, long-sleeved shirts and pants offer extensive coverage while remaining comfortable in hot weather. Avoiding direct sun exposure during peak intensity hours (typically 10 AM to 4 PM) can also significantly reduce overall radiation exposure. Seeking shade whenever possible provides natural protection. So, what's the takeaway here? Prioritize mineral sunscreens with zinc oxide and titanium dioxide, choose lotion formulations over sprays, and prioritize comprehensive sun safety strategies that protect both our health and the precious marine ecosystems.
Newsweek
5 days ago
- Newsweek
Scorpion Venom Could Help Treat Breast Cancer
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A venomous creature from the Amazon rainforest may hold the key to fighting one of the deadliest cancers affecting women today. According to the American Cancer Society, skin cancers aside, breast cancer is the most common cancer among women in the U.S.—accounting for about 30% of all new female cancer cases annually, with an estimated 42,170 women expected to die from it in 2025. Brazilian scientists have discovered that the venom of the Brotheas amazonicus scorpion contains a molecule that kills breast cancer cells in a way similar to chemotherapy, according to a groundbreaking study by researchers in Brazil. "Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer cells," said Eliane Candiani Arantes, a professor at the University of São Paulo and the project's coordinator. A stock image of a scorpion in the laboratory. A stock image of a scorpion in the laboratory. Sinhyu/iStock/Getty Images Plus The molecule in question, called BamazScplp1, is a type of peptide—a short chain of amino acids—that showed cancer-fighting properties when tested in the lab. It worka similarly to paclitaxel, a standard chemotherapy drug, by inducing necrosis, or uncontrolled cell death, in breast cancer cells. Unlike some other cell-killing processes that are regulated by the body, necrosis causes the cancer cells to burst and die—a tactic that has also been observed in other venom-based compounds. What Is Bioprospecting? Bioprospecting is the process of searching for useful compounds in nature, especially from plants, animals, and microorganisms. In this case, the team explored scorpion venom for potential bioactive molecules—substances that affect living tissues in a beneficial way, such as fighting infections or cancer. Turning Venom into Medicine—Without the Scorpions The researchers aren't milking scorpions for their venom at scale. Instead, they are using a process called heterologous expression, which means inserting the gene that produces a particular protein into another organism—often yeast or bacteria—so it can be produced in large quantities in the lab. "We also intend to obtain these molecules through heterologous expression," Arantes said, referring to BamazScplp1 and other promising compounds. One such host organism is Pichia pastoris, a species of yeast originally isolated in France in 1950. It's commonly used in biotechnology to manufacture proteins that would otherwise be difficult to source naturally. "Our idea now is to obtain this serine protease through heterologous expression [in a fragment or complete gene from a host organism that doesn't have it naturally] in Pichia pastoris," she added. The "Super Glue" Made from Snake Venom This isn't the first time researchers in Brazil have turned to venom for medical innovation. At the Center for the Study of Venoms and Venomous Animals (CEVAP), scientists developed a patented product called fibrin sealant—a kind of biological glue made by combining serinoproteinase (an enzyme found in snake venom) with cryoprecipitate, a component derived from the blood of buffalo, cattle, or sheep and is rich in fibrinogen, a protein essential for blood clotting. When mixed, the two form a fibrin network, mimicking the body's natural healing process. This sealant has been studied for uses like nerve repair, bone injury treatment and even helping restore movement after spinal cord injuries. It is currently in phase three clinical trials, the last stage before a drug can be considered for approval and widespread use. "This growth factor favors the formation of new vessels. If we combine it with colinein-1, we can create an improved fibrin sealant compared to the one being developed at CEVAP, with the possibility of expanding the industrial scale, since it can be obtained through heterologous expression," Arantes said. A Bigger Push Toward Biopharmaceutical Innovation All of this work is being carried out as part of the Center for Translational Science and Development of Biopharmaceuticals (CTS), a program aimed at turning biological discoveries into practical medical treatments. The CTS is part of a broader push by FAPESP, a public foundation in Brazil that funds scientific research. Their strategy isn't limited to scorpion venom. The team has also worked with rattlesnake proteins, including a compound called cholinein-1, and is developing another bioactive substance known as CdtVEGF, which promotes the growth of blood vessels—a potentially valuable tool in tissue regeneration. What Comes Next? The discovery of BamazScplp1 is still in the early stages. The results were shared at FAPESP Week France, a scientific conference held from June 10 to 12 in Toulouse, southern France. But the findings highlight the growing interest in nature-based compounds and how they might work alongside or even replace traditional treatments like chemotherapy. If further tests confirm its effectiveness and safety, the molecule from the scorpion could someday be developed into a new kind of anti-cancer drug, offering patients more options and possibly fewer side effects. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about breast cancer? Let us know via health@
